Chromatin profiling assays enable the mapping of protein-DNA interactions that influence chromatin modeling and gene expression.
Over the years, Chromatin ImmunoPrecipitation (ChIP) assays became the gold-standard for studying transcription factor–DNA binding interactions, nucleosome dynamics, and epigenetics (ex. histone post-translational modifications (PTMs)). This post aims at introducing the latest evolution of ChIP assays: CUTANA™ CUT&RUN and ChIC assays.

Over the last years, ChIP experts express the need for more sensitivity, faster protocols, and more reproducible results (and ideally starting from less starting cellular material). These expectations led to the emergence of new experimental antibody-based experimental approaches like Chromatin ImmunoCleavage (ChIC) assays, and Cleavage Under Targets and Release Using Nuclease (CUT&RUN) methods.

Multiplex protein assays allow multiple targets quantification in a single sample, a bit like performing up to 40 different ELISAs in one go. Outsourcing Multiplex Protein Quantification projects to experts may work out more cost effective and time saving. It saves you the hassle of setting up a new technology in your lab, and you can rely on people with years of expertise in the technology to generate quality data on the very first run. Should you wish to set it up in your own lab, some technologies are easily adaptable if you have access to the equipment.

ORF expression in Mammalian cells is very useful for many applications: protein production with HEK293, over-expression of tagged protein for immuno-tracking or immuno-precipitation, development of a cell line for drug discovery such as a cancer model expressing PD-1 or PD-L1…

Unfortunately, plasmid delivery into primary cells and cell lines is often challenging, providing low or even no transfection efficiency. The solution is a robust lentiviral system.

So, how do you identify the right lentiviral system? With the titer! The higher is the better. 10⁷TU/ml is ok… and 10⁸TU/ml is very good.

Nephropathy is a hot research topic, especially in relation to its link with Diabetes (already 6 500 publications so far referenced in pubmed to date for 2019, a third of them in relation to type I or type II diabetes). As nephropathy can lead to life endangering end-stage renal diseases (ESRDs) with a severe impact on life expectancy, a lot of research is being undertaken to find new drugs to beat this potentially severe condition. Several biomarkers of this pathology have already been identified such as CD27 antigen, kidney injury molecule 1 (KIM-1) and α1-microglobulin in relation to type I diabetes (1), in addition to the well known Clusterin, Cystatin-C, Microalbumin and Beta-2 Microglobulin.